Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus : a pilot trial

• 資料種別: 博士論文
• タイトル: Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus : a pilot trial
• 著者・編者: Obata, Fumiaki; Tani, Kenji; Yamaguchi, Harutaka; Tabata, Ryo; Bando, Hiroyasu; Imoto, Issei
• 著者標目: Obata, Fumiaki; Tani, Kenji; Yamaguchi, Harutaka; Tabata, Ryo; Bando, Hiroyasu; Imoto, Issei
• 出版事項: Faculty of Medicine Tokushima University
• 出版年月日等: 2017-02
• 出版年（W3CDTF）: 2017-02
• 並列タイトル等: 2型糖尿病患者に対するエンパグリフロジン10mgの連日投与と隔日投与の有効性と安全性の比較検討:パイロット試験; Comparison of treatment in patients
• タイトル（掲載誌）: The Journal of Medical Investigation
• 巻号年月日等（掲載誌）: 64 1-2
• 掲載巻: 64
• 掲載号: 1-2
• 掲載ページ: 50-57
• ISSN（掲載誌）: ISSN : 1349-6867; ISSN : 1343-1420
• 授与機関名: 徳島大学
• 授与年月日: 2017-04-27
• 報告番号: 甲第3093号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: sodium-glucose transporter 2 inhibitors; type 2 diabetes mellitus; every other day; empagliflozin; weight reduction
• 対象利用者: 一般
• 一般注記: The terminal elimination half-life (t1/2) of empagliflozin is 13.1 hours. Accordingly, we hypothesized that the administration of empagliflozin every other day might improve glycemic control in patients with type 2 diabetes mellitus, not being inferior to the therapy every day. We investigated the clinical effects and safety of the addition of empagliflozin every day or every other day to type 2 diabetic patients with a poor control in glycemia. Thirteen Japanese patients diagnosed as type 2 diabetes mellitus recruited to this study. Subjects were divided into two groups ; one was treatment with 10 mg of empagliflozin every day (Group A), the other was 10 mg of empagliflozin every other day (Group B). The comparable study of multiple clinical indexes between the 2 groups was made before and 8, 16, and 24 weeks after the treatment. After the treatment for 24 weeks, the HbA1c level was decreased both in group A (from 7.5%±1.1% to 6.5%±0.8%) and in group B (from 7.6%±0.8% to 7.2%±0.5%). This pilot trial suggested the possibility of 10-mg every other day administration with empagliflozin for Japanese patients with type 2 diabetes mellitus.
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.2152/jmi.64.50
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 徳島大学 : 徳島大学機関リポジトリ

目次

http://repo.lib.tokushima-u.ac.jp/files/public/11/111081/20190809175004563758/LID201705291001.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/111081/20190809175004889020/LID201705291002.pdf fulltext